Poseida Therapeutics, Inc.

143 articles about Poseida Therapeutics, Inc.

• Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

  4/18/2024

  Poseida Therapeutics, Inc. today announced that six data presentations highlighting the Company's preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.

• Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus

  4/17/2024

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy and genetic medicines company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company plans to highlight progress across its proprietary non-viral genetic engineering and delivery platform and rare disease pipeline during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.

• Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

  4/8/2024

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1.

• Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024

  4/1/2024

  Poseida Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted an inducement award to Syed Rizvi, M.D., the Company's new Chief Medical Officer.

• Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

  3/25/2024

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.

• Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

  3/19/2024

  Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, 2024 at 1:00pm PT | 4:00pm ET.

• Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

  3/13/2024

  Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.

• Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

  3/7/2024

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023. 

• Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 04, 2024

  3/4/2024

  Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, announced that the Compensation Committee of its Board of Directors granted an inducement award to an employee.

• Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones

  1/4/2024

  Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, highlighted recent progress across the company's cell and gene therapy portfolio and provided updates on anticipated upcoming milestones.

• 

  Roche Partner Poseida Touts High Response Rates for Allogeneic CAR-T Therapy

  12/11/2023

  The investigational allogeneic CAR-T therapy P-BCMA-ALLO1 appears to be more effective following strong immunosuppressive preconditioning.

• Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

  12/10/2023

  Poseida Therapeutics, Inc. announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory -rich chimeric antigen receptor -T therapy candidate.

• Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023

  11/9/2023

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023.  

• Poseida Therapeutics to Present at Two Upcoming Investor Conferences - November 7, 2023

  11/7/2023

  Poseida Therapeutics, Inc. today announced that the Company will participate in the following upcoming investor conferences in November.

• Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition

  11/2/2023

  Poseida Therapeutics, Inc. announced the acceptance of three poster presentations at the 65th American Society of Hematology Annual Meeting and Exposition being held at the San Diego Convention Center in San Diego and virtually on December 9-12, 2023.

• Poseida Therapeutics Announces Leadership Transition

  10/9/2023

  Poseida Therapeutics, Inc. announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D., currently President, Cell Therapy, to the role of President and Chief Executive Officer, each expected to be effective January 1, 2024.

• Poseida Therapeutics to Present at Two Upcoming Investor Conferences - September 5, 2023

  9/5/2023

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in September.

• Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

  8/8/2023

  Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, announced financial results for the second quarter ended June 30, 2023.

• Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update

  8/7/2023

  Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update.

• Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

  8/7/2023

  Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark Gergen, "Poseida") today announced a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy.